Treatment-refractory cutaneous Rosai-Dorfman disease responsive to oral methotrexate and topical trametinib

Christopher J Fay; Dorsa Moslehi; Christopher Iriarte; Timothy M Dang; Cesar A Virgen; Eleanor Russell-Goldman; Nicole R LeBoeuf

doi:10.1016/j.jdcr.2023.06.038

Treatment-refractory cutaneous Rosai-Dorfman disease responsive to oral methotrexate and topical trametinib

JAAD Case Rep. 2023 Jul 7:39:74-77. doi: 10.1016/j.jdcr.2023.06.038. eCollection 2023 Sep.

Authors

Christopher J Fay^{1

2}, Dorsa Moslehi³, Christopher Iriarte^{1

2

3}, Timothy M Dang^{1

2

3}, Cesar A Virgen^{1

2

3}, Eleanor Russell-Goldman^{3

4}, Nicole R LeBoeuf^{1

2

3}

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
² Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts.
⁴ Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.

No abstract available

Keywords: MEK inhibitor; Rosai–Dorfman disease; cutaneous Rosai-Dorfman disease; histiocytic disorders; methotrexate; non-Langerhans cell histiocytosis; trametinib.

Publication types

Case Reports